ALKS
ALKS
NASDAQ · Biotechnology

Alkermes Plc

$45.08
-0.81 (-1.77%)
As of Nov 5, 8:03 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.47B
Net Income
240.41M
Gross Margin
86.7%
Profit Margin
16.4%
Rev Growth
+9.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 86.7% 86.7% 61.4% 61.4%
Operating Margin 17.2% 15.5% 15.6% 13.8%
Profit Margin 16.4% 15.6% 14.1% 13.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.47B 1.34B 1.89B 1.59B
Gross Profit 1.27B 1.16B 1.16B 979.55M
Operating Income 252.69M 206.94M 295.17M 220.02M
Net Income 240.41M 196.88M 267.01M 214.03M
Gross Margin 86.7% 86.7% 61.4% 61.4%
Operating Margin 17.2% 15.5% 15.6% 13.8%
Profit Margin 16.4% 15.6% 14.1% 13.4%
Rev Growth +9.9% +9.9% +6.3% -8.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 803.02M 723.95M
Total Equity — — 3.18B 3.20B
D/E Ratio — — 0.25 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 258.22M 223.21M 438.15M 351.76M
Free Cash Flow — — 233.31M 225.75M